Activin/myostatin type II receptor

Assets acting on this target.

Class
Activin type II receptor signaling blocker (activin/myostatin)

The activin/myostatin type II receptors (ActRIIA and ActRIIB) are cell-surface receptors expressed on skeletal muscle and other tissues that receive signals from members of the TGF-beta superfamily, chiefly myostatin (also called GDF-8) and the activins. Under normal physiology, these ligands act as negative regulators of muscle growth, restraining the size and number of muscle fibers. Diseases marked by muscle wasting or weakness (including spinal muscular atrophy, sarcopenia, cachexia associated with chronic illness, and certain rare bone and connective-tissue disorders) arise in part because this inhibitory signal remains active while muscle-building capacity is reduced. Therapeutic agents in this class work by intercepting either the receptor itself or its upstream ligands, thereby releasing muscle tissue from this restraint and promoting growth in muscle mass and strength. Approaches vary: some antibodies bind the shared type II receptor broadly, blocking multiple ligands at once, while others selectively neutralize a single ligand, such as myostatin or activin A. This distinction matters because the receptor also participates in processes beyond muscle, so the breadth of blockade shapes both the extent of anabolic benefit and the range of biological systems affected.

By indication

Related mechanisms

Activin/myostatin type II receptor drugs compared

4 drugs, stage by indication
4 drugs acting on Activin/myostatin type II receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
taldefgrobep alfaBiohavenprotein (adnectin)Phase 3Phase 3 in Spinal Muscular Atrophy; Phase 2 in Obesity
bimagrumabEli Lilly, Novartismonoclonal antibodyPhase 2Phase 2 in Obesity
AZD1043AstraZenecamonoclonal antibodyPhase 1Phase 1 in Obesity
REGN20934Regeneron Pharmaceuticalsmonoclonal antibodyPhase 1Phase 1 in Obesity

← all mechanisms